Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up
2014
Authors
Markićević, MilanDžodić, Radan R.
Buta, Marko
Kanjer, Ksenija
Mandušić, Vesna
Nešković-Konstantinović, Zora
Nikolić-Vukosavljević, Dragica
Article (Published version)
Metadata
Show full item recordAbstract
Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statisti...cal analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.
Keywords:
trefoil factor 1 / cut-off value / disease-free interval / early breast carcinoma / early follow-upSource:
International Journal of Medical Sciences, 2014, 11, 7, 663-673Funding / projects:
- Molecular biomarkers of breast carcinoma and follow-up-dependent changes of thier relevance (RS-175068)
- Molecular determinants for tumor marker design (RS-173049)
DOI: 10.7150/ijms.8194
ISSN: 1449-1907
PubMed: 24843314
WoS: 000344636200002
Scopus: 2-s2.0-84899732363
Collections
Institution/Community
VinčaTY - JOUR AU - Markićević, Milan AU - Džodić, Radan R. AU - Buta, Marko AU - Kanjer, Ksenija AU - Mandušić, Vesna AU - Nešković-Konstantinović, Zora AU - Nikolić-Vukosavljević, Dragica PY - 2014 UR - https://vinar.vin.bg.ac.rs/handle/123456789/203 AB - Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up. T2 - International Journal of Medical Sciences T1 - Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up VL - 11 IS - 7 SP - 663 EP - 673 DO - 10.7150/ijms.8194 ER -
@article{ author = "Markićević, Milan and Džodić, Radan R. and Buta, Marko and Kanjer, Ksenija and Mandušić, Vesna and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica", year = "2014", abstract = "Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive factor for positive response to endocrine therapy in breast cancer patients. The aim of our study was to examine TFF1 level distribution in breast carcinomas in order to distinguish estrogen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of TFF1 status in early breast cancer during the first 3 years of follow-up. Methods. The study included 226 patients with primary operable invasive early breast carcinomas for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor (ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples by immunoradiometric assay or by use of classical biochemical method, respectively. Non-parametric statistical tests were applied for data analyses. Results. Statistical analysis revealed that TFF1 levels were significantly higher in premenopausal patients (p=0.02), or in tumors with: lower histological grade (p LT 0.001), positive ER or PR status (p LT 0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expression in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER-and and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients at opposite risk for relapse. Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and help in making decision on administering adjuvant therapy for early breast cancer patients during the first 3 years of follow-up.", journal = "International Journal of Medical Sciences", title = "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up", volume = "11", number = "7", pages = "663-673", doi = "10.7150/ijms.8194" }
Markićević, M., Džodić, R. R., Buta, M., Kanjer, K., Mandušić, V., Nešković-Konstantinović, Z.,& Nikolić-Vukosavljević, D.. (2014). Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. in International Journal of Medical Sciences, 11(7), 663-673. https://doi.org/10.7150/ijms.8194
Markićević M, Džodić RR, Buta M, Kanjer K, Mandušić V, Nešković-Konstantinović Z, Nikolić-Vukosavljević D. Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up. in International Journal of Medical Sciences. 2014;11(7):663-673. doi:10.7150/ijms.8194 .
Markićević, Milan, Džodić, Radan R., Buta, Marko, Kanjer, Ksenija, Mandušić, Vesna, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, "Trefoil Factor 1 in Early Breast Carcinoma: A Potential Indicator of Clinical Outcome during the First 3 Years of Follow-Up" in International Journal of Medical Sciences, 11, no. 7 (2014):663-673, https://doi.org/10.7150/ijms.8194 . .